Evaluation of the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6–11 Years: Actual Observations and Clinical Perspectives.
Cystic fibrosis causes exercise limitation due to impaired lung function and other complications, which in turn increases the chance of mortality. CFTR modulators, particularly the elexacaftor/tezacaftor/ivacaftor (ETI) combination, improve lung function in children older than 6 years in real-life s...
| Autores: | , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Universidad Europea (UEM) |
| Repositorio: | ABACUS. Repositorio de Producción Científica |
| Idioma: | inglés |
| OAI Identifier: | oai:abacus.universidadeuropea.com:11268/16408 |
| Acceso en línea: | https://hdl.handle.net/11268/16408 |
| Access Level: | acceso abierto |
| Palabra clave: | Niño Fibrosis Quística Calidad de vida Salud Aparato respiratorio Salud materno-infantil Goal 3: Ensure healthy lives and promote well-being for all at all ages |
| Sumario: | Cystic fibrosis causes exercise limitation due to impaired lung function and other complications, which in turn increases the chance of mortality. CFTR modulators, particularly the elexacaftor/tezacaftor/ivacaftor (ETI) combination, improve lung function in children older than 6 years in real-life studies. This study aimed to assess the impact of ETI on aerobic capacity in children with CF aged 6–11 years under real-life conditions and to evaluate whether prior CFTR modulator treatment affects these outcomes. |
|---|